Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis

被引：18
|
作者：
Lissandre, S. [1 ]
Bay, J-O [2 ]
Cahn, J-Y [3 ]
Porcher, R. [4 ]
Cacheux, V. [2 ]
Cabrespine, A. [2 ]
Cornillon, J. [5 ]
Cassinat, B. [6 ]
de Latour, R. Peffault [1 ]
Socie, G. [1 ]
Robin, M. [1 ]
机构：
[1] Univ Paris 07, St Louis Hosp, Serv Hematol Greffe, F-75475 Paris 10, France
[2] Hop Hotel Dieu, Serv Hematol, Clermont Ferrand, France
[3] Michallon Hosp, Serv Hematol, Grenoble, France
[4] Univ Paris 07, St Louis Hosp, Dept Biostat, F-75475 Paris 10, France
[5] Inst Cancerol Loire, Serv Hematol, St Etienne, France
[6] Univ Paris 07, St Louis Hosp, Lab Biol Cellulaire, F-75475 Paris 10, France
来源：
BONE MARROW TRANSPLANTATION | 2011年 / 46卷 / 04期
关键词：
myelofibrosis; allogeneic haematopoietic stem-cell transplantation; JAK2-V617F mutation; CMV; GvHD; AGNOGENIC MYELOID METAPLASIA; INTERNATIONAL WORKING GROUP; ESSENTIAL THROMBOCYTHEMIA; MARROW-TRANSPLANTATION; POLYCYTHEMIA-VERA; GRUPPO-ITALIANO; SCORING SYSTEM; MIDOLLO-OSSEO; CHRONIC GRAFT; HOST-DISEASE;
D O I：
10.1038/bmt.2010.276
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
Allogeneic haematopoietic stem-cell transplantation (HSCT) is the only curative treatment for myelofibrosis. We retrospectively analyzed the outcome of patients who underwent allogeneic HSCT, 1994-2008, and the potential risk factors affecting non-relapse mortality (NRM), OS and relapse-free survival (RFS). A total of 39 patients, 15-65 (median 49) years old, diagnosed with primary (n = 27) or secondary (n = 12) myelofibrosis underwent HSCT (25 related and 14 unrelated). In ten patients, disease had transformed into acute leukaemia. Lille prognosis score was low for 9, intermediate for 16 and high for 14 patients. The conditioning regimen was myeloablative (MAC) for 15 and reduced-intensity (RIC) fludarabine-based for 24, with successful engraftment in 38 patients. A total of 31 patients developed grade I-IV GvHD; 19 developed chronic GvHD. The 3-year OS, RFS and NRM rates (95% confidence interval) were 60% (42-74), 54% (37-59) and 30% (30-45), respectively. Bone Marrow Transplantation (2011) 46, 557-561; doi:10.1038/bmt.2010.276; published online 1 November 2010
引用
收藏
页码：557 / 561
页数：5
相关论文
共 50 条
  • [1] Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis
    S Lissandre
    J-O Bay
    J-Y Cahn
    R Porcher
    V Cacheux
    A Cabrespine
    J Cornillon
    B Cassinat
    R Peffault de Latour
    G Socie
    M Robin
    [J]. Bone Marrow Transplantation, 2011, 46 : 557 - 561
  • [2] Allogeneic stem-cell transplantation for myelofibrosis
    Lavi, Noa
    Rowe, Jacob M.
    Zuckerman, Tsila
    [J]. CURRENT OPINION IN HEMATOLOGY, 2017, 24 (06) : 475 - 480
  • [3] Allogeneic hematopoietic stem-cell transplantation for myelofibrosis
    Zhang, Lining
    Yang, Fan
    Feng, Sizhou
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [4] Opening opinion: allogeneic haematopoietic stem-cell transplantation
    Olson, Timothy
    [J]. LANCET HAEMATOLOGY, 2023, 10 (10): : E798 - E800
  • [5] Outcome Improvement After Allogeneic Stem-Cell Transplantation in Myelofibrosis
    Kroeger, Nicolaus
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (07) : 629 - +
  • [6] Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review
    Farhadfar, Nosha
    Cerquozzi, Sonia
    Patnaik, Mrinal
    Tefferi, Ayalew
    [J]. JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (07) : 611 - +
  • [7] Cerebral toxoplasmosis following allogeneic haematopoietic stem-cell transplantation
    Ozkan, H.
    Hakko, E.
    Karaman, K.
    Ozer, U.
    Gulbas, Z.
    [J]. BONE MARROW TRANSPLANTATION, 2013, 48 : S329 - S330
  • [8] Myeloablative allogeneic haematopoietic stem cell transplantation for myelofibrosis with myeloid metaplasia
    Ditschkowski, M.
    Keller, M. T.
    Elmaagacli, A. H.
    Trenschel, R.
    Steckel, N. K.
    Koldehoff, M.
    Schulte, C.
    Beelen, D.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 39 : S9 - S10
  • [9] Risk stratification systems for allogeneic haematopoietic stem-cell transplantation
    Pabst, Thomas
    Bacher, Ulrike
    [J]. LANCET HAEMATOLOGY, 2021, 8 (03): : E166 - E167
  • [10] Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis
    Robin, Marie
    Esperou, Helene
    de Latour, Regis Peffault
    Petropoulou, Anna D.
    Xhaard, Alienor
    Ribaud, Patricia
    Socie, Gerard
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (06) : 721 - 724
12345